Last updated 2026-07-30
TL;DR
Sirolimus extends lifespan in every mouse study the NIA has run, sometimes by 9-14% even when started late in life. But there is no completed human lifespan trial. Off-label use means real risks (mouth ulcers, immune suppression, lipid changes) with unproven human longevity benefit. Worth it depends entirely on your risk tolerance and whether you value strong preclinical data over waiting for proof.
What is sirolimus, and is it the same thing as rapamycin?
Sirolimus and rapamycin are the same molecule. Rapamycin was the original name, discovered in a soil sample from Easter Island (Rapa Nui) in the 1970s. Sirolimus is the generic drug name used on the actual prescription label in the US [1]. You'll see both terms used interchangeably in research and in longevity circles, and that's fine, they're not different formulations or different drugs. The FDA approved sirolimus in 1999 as an immunosuppressant to prevent organ transplant rejection, marketed as Rapamune [1]. Since then, related formulations have picked up narrow approvals: Fyarro for a rare soft tissue cancer (advanced malignant PEComa) and Hyftor as a topical gel for skin lesions from tuberous sclerosis complex [2]. None of these approvals cover aging, lifespan extension, or general "longevity" use. Every person taking low-dose intermittent sirolimus for anti-aging purposes is doing so off-label, on a prescriber's judgment, not on an FDA-approved indication.
Does sirolimus actually extend lifespan? What does the animal data show?
Yes, in mice, repeatedly and consistently. This is the strongest part of the sirolimus story and the reason anyone is having this conversation at all. The National Institute on Aging's Interventions Testing Program (ITP), which tests candidate longevity compounds across three lab sites using genetically diverse mice, found that rapamycin increased median lifespan in both sexes, and it worked even when dosing started at 600 days old, which is roughly equivalent to a 60-year-old human [3]. In the original 2009 Nature paper, rapamycin extended median lifespan by 9% in males and 13% in females when started late in life (at 600 days) [4]. Later ITP cohorts using higher doses or different encapsulations pushed those numbers further, with some cohorts showing gains of 20% or more in females at higher doses [5]. This is genuinely rare in aging research. Very few compounds have replicated across independent labs and multiple genetic backgrounds the way rapamycin has. But mice are not people, and the ITP itself does not claim otherwise. Mouse trials run 2-3 years. Human trials would need to run decades to measure lifespan directly, which is exactly why nobody has done one. That gap between excellent mouse data and zero human lifespan data is the single most important thing to understand before deciding if this is worth it for you. If you want the full picture on what the animal and human evidence actually shows, see sirolimus reviews.
Has anyone actually tested sirolimus for lifespan or aging in humans?
No completed trial has measured whether sirolimus extends human lifespan or slows human aging, and none currently could, because a real answer requires following people for decades. What exists instead is a handful of short trials looking at surrogate markers: immune function, frailty measures, skin aging, and biomarkers thought to track with aging. The most cited human study is a 2014 trial from Novartis using an mTOR inhibitor related to sirolimus (RAD001, everolimus) in elderly volunteers, which found improved response to influenza vaccination, a proxy for immune function, not a lifespan outcome [6]. A small trial out of the PEARL study (led by researchers affiliated with AgelessRx) looked at low-dose rapamycin in healthy adults over 48 weeks and reported some improvements in self-reported measures and lean mass, but it was small, not powered for hard clinical endpoints, and has real limitations researchers have pointed out openly [7]. There is no FDA-approved indication for aging or longevity, and the agency does not recognize "aging" as a treatable condition, which is itself a barrier to running the kind of trial that would settle this [2]. Anyone telling you human data "proves" sirolimus extends life is overstating what exists. For a timeline of what data actually exists and when, read sirolimus results timeline.
What are the real risks and side effects of off-label sirolimus?
The three risks that come up most in off-label, intermittent-dosing protocols are mouth ulcers (stomatitis), immune suppression, and metabolic changes, particularly lipid shifts. These aren't rare or theoretical; they show up in the transplant literature where sirolimus has been used at much higher, continuous doses for over two decades. Mouth ulcers (aphthous-type stomatitis) are one of the most commonly reported side effects in sirolimus prescribing information, and they're dose-related, more common at higher blood levels [8]. In the low-dose, once-weekly or twice-weekly protocols that longevity users typically follow, ulcers tend to be milder and less frequent than in transplant patients on daily dosing, but they still happen and are one of the top reasons people either lower their dose or stop. Immune suppression is the core pharmacology of the drug, that's literally why it's approved for transplant rejection. At transplant doses, patients face meaningfully higher infection risk. At the low, intermittent doses used off-label for longevity, the immune effect appears smaller and may be more selective (some researchers argue intermittent dosing spares certain immune functions while still hitting mTOR in relevant tissues), but this claim rests on mouse mechanism studies and small human biomarker data, not on outcomes trials confirming people on this protocol get sick less or more often [7]. Metabolic effects include increases in LDL cholesterol and triglycerides, and in some cases new-onset or worsened glucose intolerance, both listed in FDA prescribing information for sirolimus at approved doses [8]. Anyone starting this protocol should get baseline lipids and glucose checked and monitor periodically, more than start and hope. Other listed effects in transplant use include delayed wound healing and elevated risk of certain infections, which matter more if you have upcoming surgery or dental work planned [8]. For a straight list of upsides and downsides side by side, see sirolimus pros and cons.
How much does off-label sirolimus cost, and is that cost justified?
Generic sirolimus is cheap as a drug itself, often in the range of $20-60 per month for a typical low-dose weekly protocol when filled through standard pharmacy channels, though this varies by pharmacy, dose, and insurance status (which usually doesn't apply, since insurance won't cover an off-label longevity use). The bigger cost driver is usually the clinical relationship: a prescriber consultation, baseline labs (lipid panel, fasting glucose, CBC, kidney and liver function), and periodic follow-up labs, which can add several hundred dollars a year depending on how thorough the monitoring is. Whether that's "worth it" is a value judgment, not a fact. If you're paying for a legitimate prescriber who orders baseline and follow-up labs and adjusts dose based on your bloodwork, that's a reasonable use of money for something you're taking off-label with real, known side effects. If you're buying loose pills online with no bloodwork and no prescriber oversight, you're paying for a drug with real immunosuppressive and metabolic effects and getting none of the safety monitoring that makes off-label use defensible. That's not a bargain, that's a risk with no upside pricing it in.
Who is actually a good candidate for trying sirolimus off-label?
Nobody is a slam-dunk candidate, because there's no human trial proving benefit, but some people have a more reasonable risk-benefit case than others. Middle-aged and older adults without active infections, without a history of poor wound healing, without uncontrolled diabetes or significant dyslipidemia, and who are willing to do baseline and follow-up labs, are the group most commonly discussed in the (largely observational, non-trial) literature on off-label use. People who should think hard before starting, or should certainly not self-prescribe, include anyone on other immunosuppressive medication, anyone with a history of poor wound healing, anyone with active or recent infections, anyone with poorly controlled lipids or blood sugar, anyone pregnant or planning pregnancy, and anyone with upcoming elective surgery or significant dental work, given the drug's documented effects on wound healing and infection risk in FDA labeling [8]. The mouse data that supports late-life dosing (the ITP study starting at 600 days, roughly a 60-year-old equivalent) [4] is often cited as reassurance that starting later in life still shows benefit in mice. That's true, but it's still a mouse finding. It doesn't mean starting at 60 in a human carries the same benefit-to-risk ratio; it just means the mouse experiment that showed benefit happened to start late.
What results should someone realistically expect, and on what timeline?
Realistically: you should expect no measurable change in how long you live, because nobody can measure that in real time, and you should expect the actual, checkable changes to show up in bloodwork and side effects over weeks to months, not in how you feel day to day. Some users report subjective changes (skin, joint comfort, energy) within the first few months, but these are self-reported and not validated against placebo in controlled human trials. What you can track is concrete: lipid panels typically get rechecked at 4-12 weeks after starting, since LDL and triglyceride changes are a known and monitorable effect [8]. Mouth ulcers, if they're going to happen, usually show up within the first several weeks of a new dose. Full blood counts and kidney/liver function are typically part of routine repeat labs at 3-6 month intervals for most off-label protocols, though exact intervals vary by prescriber. For a week-by-week and month-by-month breakdown of what people commonly experience when starting, read sirolimus first month what to expect, and for how outcomes commonly play out over a longer stretch, see sirolimus before and after.
What does "success" even mean for a longevity drug with no human trial?
This is the honest, uncomfortable core of the question. For an FDA-approved drug treating a diagnosable condition, success is measurable: tumor shrinks, transplant survives, symptoms resolve. For sirolimus used off-label for longevity, there is no equivalent measurable endpoint available to an individual user, because human lifespan extension can't be observed in one person's lifetime in real time, and no biomarker has been validated as a proven stand-in for it in humans. What people actually track instead: lipid and glucose numbers staying in range, absence of concerning side effects, and occasionally inflammatory or biological-age biomarker panels, none of which have been shown in a controlled human trial to predict actual lifespan extension. That doesn't make them worthless as safety monitoring, it just means they're not proof of the thing people are hoping for. If you want a realistic read on what percentage of people continue the protocol, tolerate it well, or stop due to side effects, based on the observational and self-reported data that exists, see sirolimus success rate. Treat any number there as descriptive of a user population, not as a clinical trial result.
How does sirolimus compare to other longevity drug candidates like metformin or acarbose?
| Sirolimus (rapamycin) | Approved for transplant rejection, Fyarro/Hyftor for specific conditions; NOT for aging [1] [2] | ITP: 9-14%+ median lifespan gain in mice, replicated across sites [3] [4] | Immune suppression, mouth ulcers, lipid changes [8] | |
|---|---|---|---|---|
| Metformin | Approved for type 2 diabetes | Mixed in ITP mouse cohorts, not consistently significant alone [5] | GI upset, B12 deficiency long-term | |
| Acarbose | Approved for type 2 diabetes | Lifespan extension in some ITP cohorts, mainly males | GI side effects (gas, bloating) | None of these three drugs is approved for longevity use in humans. The comparison that matters for a buyer isn't just "which mouse effect is biggest," it's also side effect burden and how much human safety data already exists from other approved uses. Metformin has decades of human safety data at diabetic doses; sirolimus has decades of human safety data too, but at continuous, higher immunosuppressive doses in transplant patients, not at the low intermittent doses used off-label for longevity. |
Sirolimus has the strongest and most consistently replicated lifespan-extension data in mice of any candidate compound tested by the NIA's Interventions Testing Program, including compared to metformin and acarbose, both of which have also shown some lifespan benefit in ITP testing but generally smaller or less consistent effects than rapamycin across cohorts [5]. Acarbose showed lifespan extension particularly in males in some ITP cohorts; metformin's ITP results have been more mixed and, in at least one high-profile cohort, metformin alone did not significantly extend lifespan, though it showed benefit combined with rapamycin in some analyses [5]. | Compound | Human approval status | Strongest lifespan evidence | Notable off-label risk |
Is sirolimus legal to buy, and do I need a prescription?
Yes, sirolimus is a prescription-only medication in the United States, it is not sold over the counter, and using it without a prescription from a licensed provider means using an unregulated product with unknown quality and dosing, on top of using an immunosuppressive drug with no clinical oversight. The FDA-approved product label covers only transplant rejection prevention and the narrow oncology and dermatology indications noted earlier [1] [2]; a provider prescribing it for longevity is doing so within their legal right to prescribe off-label, which is a normal and legal part of medical practice, but the drug itself still requires a valid prescription to obtain legitimately. The safest route is working with a prescriber who orders baseline labs, discusses your specific health history and medication list, and has a compounding or fulfillment pharmacy they trust for accurate dosing and quality control. Sirolimus Rx connects patients with providers who review your history before prescribing, and prescriptions are filled through a licensed pharmacy partner, not compounded or sold directly by Sirolimus Rx itself.
So, is sirolimus actually worth it?
If you're asking whether sirolimus is proven to extend human life, the honest answer is no, not yet, and possibly not for years, because nobody has run the decades-long trial that would prove it. If you're asking whether the underlying science is serious enough to justify informed, monitored, off-label use for some people, the answer is more nuanced: the mouse data is about as strong as preclinical aging data gets, replicated by an independent federal testing program across multiple labs [3] [4], and the drug's side effect profile is well characterized because it's been used in transplant medicine since 1999 [1]. Worth it, for you specifically, comes down to three honest questions. Do you accept meaningful uncertainty in exchange for acting on strong-but-not-definitive evidence? Are you willing to pay for real monitoring (labs, a prescriber who checks in) rather than just buying pills? And do you have any of the risk factors, active infection, poor wound healing history, uncontrolled metabolic disease, upcoming surgery, that tip the calculus against trying it right now? If you answer honestly and land on yes, the responsible path is a provider-reviewed prescription and pharmacy-dispensed product, not an unregulated purchase. If you land on no, waiting for more human data is a completely reasonable and defensible choice too. Nobody should feel behind for waiting on proof.
Frequently asked questions
Is sirolimus the same as rapamycin?
Yes. Rapamycin is the original compound name; sirolimus is the generic drug name on US prescription labels. They are chemically identical. You'll see both used in research papers and longevity discussions interchangeably, and neither term refers to a different formulation or dose.
Does sirolimus extend lifespan in humans?
No completed human trial has measured this, and none currently could since it requires decades of follow-up. The strong lifespan data comes from mouse studies through the NIA's Interventions Testing Program, which found 9-14% or greater median lifespan increases, but this has not been proven to translate to humans.
What is the FDA-approved use for sirolimus?
Sirolimus is FDA-approved to prevent organ transplant rejection (as Rapamune, approved 1999), and related formulations are approved for a rare cancer (Fyarro) and a tuberous sclerosis skin condition (Hyftor). It has no FDA approval for aging, longevity, or general anti-aging use; that use is entirely off-label.
What are the biggest risks of taking sirolimus off-label for longevity?
The most commonly reported risks are mouth ulcers (stomatitis), immune suppression, and metabolic changes including elevated LDL cholesterol and triglycerides, all documented in FDA prescribing information at approved doses. Lower, intermittent longevity dosing may reduce but does not eliminate these risks.
How much does sirolimus cost for off-label longevity use?
Generic sirolimus itself often runs roughly $20-60 per month at typical low-dose protocols, though pricing varies by pharmacy and dose. The larger ongoing cost is usually prescriber consultation and baseline/follow-up lab work, which can add several hundred dollars a year but is important for safety monitoring.
Can I buy sirolimus without a prescription?
No. Sirolimus is a prescription-only medication in the United States. Buying it without a valid prescription means using an unregulated product with unknown quality and no clinical oversight for an immunosuppressive drug with real side effects.
Who should not take sirolimus off-label?
People with active infections, poor wound healing history, uncontrolled diabetes or significant dyslipidemia, those on other immunosuppressants, anyone pregnant or planning pregnancy, and anyone with upcoming surgery or major dental work should discuss these specific risk factors carefully with a prescriber before considering it.
How is sirolimus different from everolimus?
Everolimus is a related mTOR inhibitor, chemically similar to sirolimus but with different pharmacokinetics (shorter half-life). It's approved for some transplant and oncology uses. Some human aging-adjacent research, like a 2014 Novartis trial on immune response, used everolimus (RAD001), not sirolimus directly.
What did the NIA Interventions Testing Program actually find about rapamycin?
The NIA's ITP found rapamycin increased median lifespan in genetically diverse mice at multiple independent lab sites, including when dosing started at 600 days old (roughly a 60-year-old human equivalent), with the original 2009 study showing 9% and 13% median lifespan increases in males and females respectively.
Is there a human trial testing sirolimus for aging currently underway?
Small trials exist looking at short-term biomarkers, immune function, and self-reported outcomes (like the PEARL study), but none have completed a trial measuring actual human lifespan extension, and such a trial would require decades of follow-up to produce a direct answer.
Does low-dose intermittent dosing avoid the side effects seen in transplant patients?
It may reduce some risks, since transplant doses are continuous and much higher, but low-dose intermittent protocols still carry documented risks including mouth ulcers, lipid changes, and some degree of immune suppression. No controlled human trial has quantified the exact risk reduction from intermittent versus continuous dosing.
How does sirolimus compare to metformin for longevity?
Sirolimus has shown larger and more consistently replicated lifespan extension in NIA ITP mouse studies than metformin, which has had mixed results alone in mouse cohorts. Metformin has decades more human safety data at diabetic doses, while sirolimus's extensive human data comes from higher-dose transplant use, not low-dose longevity protocols.
Sources
- FDA, Rapamune (sirolimus) approval history and label: Sirolimus (Rapamune) was FDA-approved in 1999 to prevent organ transplant rejection
- FDA, Fyarro (sirolimus protein-bound) approval: Fyarro is FDA-approved for advanced malignant PEComa, a narrow oncology indication, not for aging
- National Institute on Aging, Interventions Testing Program: The NIA's Interventions Testing Program tests candidate longevity compounds like rapamycin across multiple lab sites in genetically diverse mice
- Harrison et al., Nature 2009: Rapamycin extended median lifespan by approximately 9% in males and 13% in females when started at 600 days of age in mice
- Strong et al., Aging Cell, NIA ITP results on rapamycin, acarbose, and metformin: ITP cohorts found variable lifespan effects across rapamycin, acarbose, and metformin, with rapamycin showing the most consistent benefit
- Mannick et al., Science Translational Medicine 2014: An mTOR inhibitor (RAD001/everolimus) improved influenza vaccine response in elderly volunteers, a proxy for immune function
- PEARL trial (rapamycin in healthy adults), published results: A small trial of low-dose rapamycin in healthy adults over 48 weeks reported some improvements in self-reported measures and lean mass, with acknowledged study limitations
- FDA, Rapamune (sirolimus) prescribing information: Sirolimus prescribing information lists mouth ulcers (stomatitis), elevated LDL/triglycerides, and increased infection risk as documented side effects